12.02
0.00%
0.00
After Hours:
12.02
Replimune Group Inc stock is traded at $12.02, with a volume of 330.63K.
It is up +0.00% in the last 24 hours and up +3.98% over the past month.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.
See More
Previous Close:
$12.02
Open:
$12.08
24h Volume:
330.63K
Relative Volume:
0.53
Market Cap:
$821.22M
Revenue:
-
Net Income/Loss:
$-209.96M
P/E Ratio:
-4.0471
EPS:
-2.97
Net Cash Flow:
$-176.27M
1W Performance:
-2.12%
1M Performance:
+3.98%
6M Performance:
+72.95%
1Y Performance:
-15.35%
Replimune Group Inc Stock (REPL) Company Profile
Name
Replimune Group Inc
Sector
Industry
Phone
(781) 222-9600
Address
500 UNICORN PARK, WOBURN, MA
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-17-23 | Resumed | Piper Sandler | Overweight |
Nov-19-21 | Initiated | Piper Sandler | Overweight |
Oct-15-21 | Resumed | BTIG Research | Buy |
Nov-17-20 | Initiated | BTIG Research | Buy |
Nov-02-20 | Initiated | Jefferies | Buy |
Oct-15-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
Jul-01-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
May-05-20 | Initiated | Barclays | Overweight |
Sep-04-19 | Initiated | ROTH Capital | Buy |
Jul-23-19 | Initiated | Chardan Capital Markets | Buy |
Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
Jul-08-19 | Initiated | H.C. Wainwright | Buy |
Apr-25-19 | Initiated | Wedbush | Outperform |
Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
Aug-14-18 | Initiated | JP Morgan | Overweight |
Aug-14-18 | Initiated | Leerink Partners | Outperform |
View All
Replimune Group Inc Stock (REPL) Latest News
Vanguard Group's Strategic Acquisition in Replimune Group Inc - GuruFocus.com
Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - The Manila Times
Non-melanoma Skin Cancer is Predicted to Exhibit Remarkable Growth During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.
SG Americas Securities LLC Invests $251,000 in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune Group, Inc. (NASDAQ:REPL) Given Average Recommendation of "Buy" by Analysts - MarketBeat
It would be worthwhile to take a closer look at Replimune Group Inc (REPL) - US Post News
Daily Progress: Replimune Group Inc (REPL) Drop -7.06, Closing at 10.67 - The Dwinnex
Replimune Group Inc [REPL] Insider Selling: Time to sell? - Knox Daily
Replimune Group Inc Inc. (REPL) Price Performance: A Comparative Analysis with Competitors - The InvestChronicle
Replimune Group (NASDAQ:REPL) Stock Price Down 5.2%Here's What Happened - MarketBeat
Learn to Evaluate (REPL) using the Charts - Stock Traders Daily
Cubist Systematic Strategies LLC Buys 53,313 Shares of Replimune Group, Inc. (NASDAQ:REPL) - MarketBeat
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Gaining Ground: Replimune Group Inc (REPL) Closes Higher at 11.74, Up 3.62 - The Dwinnex
Investing in Replimune Group Inc (REPL) Is Getting More Attractive - Knox Daily
Replimune Group, Inc. (NASDAQ:REPL) Shares Sold by Dimensional Fund Advisors LP - MarketBeat
Morgan Stanley's Strategic Reduction in Replimune Group Inc Holdings - GuruFocus.com
Cubist Systematic Strategies LLC Increases Position in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune Group, Inc. (NASDAQ:REPL) Shares Purchased by Millennium Management LLC - MarketBeat
Chief Financial Officer Hill Emily Luisa sale 8,938 shares of Replimune Group Inc [REPL] - Knox Daily
Insiders At Replimune Group Sold US$863k In Stock, Alluding To Potential Weakness - Simply Wall St
Replimune Group (NASDAQ:REPL) Sees Strong Trading Volume - MarketBeat
REPL’s Stock Market Adventure: 41.16% YTD Growth Amidst Volatility - The InvestChronicle
Replimune Group (NASDAQ:REPL) Trading Up 6.1% - Defense World
Is it possible to buy Replimune Group Inc(REPL) shares at a good price now? - US Post News
Replimune to Present at Two Upcoming Investor Conferences - The Manila Times
Replimune Group, Inc. (NASDAQ:REPL) Shares Sold by XTX Topco Ltd - Defense World
Keeping an Eye on Replimune Group Inc (REPL) After Insider Trading Activity - Knox Daily
Analytical Overview: Replimune Group Inc (REPL)’s Ratios Tell a Financial Story - The Dwinnex
Replimune Group Inc (REPL) expanding its growth trajectory ahead - SETE News
Replimune Group's SWOT analysis: biotech stock poised for growth amid challenges - Investing.com
Point72 DIFC Ltd Makes New $57,000 Investment in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Deerfield Management Company L.P. Series C Has $264,000 Stake in Replimune Group, Inc. (NASDAQ:REPL) - MarketBeat
Deerfield Management Company L.P. Series C Has $264,000 Stock Holdings in Replimune Group, Inc. (NASDAQ:REPL) - MarketBeat
An analyst sees good growth prospects for Replimune Group Inc (REPL) - SETE News
Point72 Asia Singapore Pte. Ltd. Makes New $443,000 Investment in Replimune Group, Inc. (NASDAQ:REPL) - MarketBeat
Replimune Group (NASDAQ:REPL) Stock Price Up 3.8% on Analyst Upgrade - MarketBeat
Financial Metrics Unveiled: Replimune Group Inc (REPL)’s Key Ratios in the Spotlight - The Dwinnex
JPMorgan Chase & Co. Increases Replimune Group (NASDAQ:REPL) Price Target to $17.00 - MarketBeat
Replimune Group (NASDAQ:REPL) Given New $17.00 Price Target at JPMorgan Chase & Co. - Defense World
A stock that deserves closer examination: Replimune Group Inc (REPL) - US Post News
Rhumbline Advisers Buys 5,732 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune Group, Inc. (NASDAQ:REPL) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Replimune Group, Inc. (NASDAQ:REPL) Receives Average Rating of “Buy” from Analysts - Defense World
Replimune Group (NASDAQ:REPL) Shares Gap Up to $11.03 - Defense World
Replimune Group, Inc. (NASDAQ:REPL) Shares Bought by Bank of New York Mellon Corp - Defense World
Arizona State Retirement System Takes Position in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune Group (NASDAQ:REPL) Shares Down 6.4% - Defense World
Its Stock Has Paid Off Big Time For Replimune Group Inc - SETE News
Replimune Group (NASDAQ:REPL) Rating Reiterated by HC Wainwright - Defense World
Are Replimune Group Inc’shares a good deal? - US Post News
Replimune Group Inc Stock (REPL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Replimune Group Inc Stock (REPL) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Xynos Konstantinos | Chief Medical Officer |
Jun 07 '24 |
Sale |
7.50 |
15,881 |
119,108 |
117,131 |
Sarchi Christopher | Chief Commercial Officer |
May 16 '24 |
Sale |
6.47 |
2,218 |
14,350 |
92,252 |
Schwendenman Andrew | Chief Accounting Officer |
May 16 '24 |
Sale |
6.47 |
2,298 |
14,868 |
38,238 |
Love Colin | Chief Operating Officer |
May 16 '24 |
Sale |
6.47 |
17,615 |
113,969 |
777,345 |
Astley-Sparke Philip | Executive Chairman |
May 16 '24 |
Sale |
6.47 |
37,928 |
245,394 |
1,487,350 |
Coffin Robert | Director |
May 16 '24 |
Sale |
6.47 |
11,464 |
74,172 |
1,821,872 |
Patel Sushil | Chief Executive Officer |
May 16 '24 |
Sale |
6.47 |
20,194 |
130,655 |
212,014 |
Xynos Konstantinos | Chief Medical Officer |
May 16 '24 |
Sale |
6.47 |
6,367 |
41,194 |
133,012 |
Xynos Konstantinos | Chief Medical Officer |
Nov 16 '23 |
Sale |
10.92 |
7,313 |
79,858 |
112,714 |
Sarchi Christopher | Chief Commercial Officer |
Nov 16 '23 |
Sale |
10.92 |
5,255 |
57,385 |
72,245 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):